Here it is, from The Street.com:
. . . .Merck downgraded at Citigroup from Buy to Hold, Citigroup said. $39 price target. Company is halting progress on Vorapaxar, which was its best near-term prospect. . . .
Ya’ think? I’ve said $37 was fully valued for over a year — while all the others pegged $45 and above as full value on Merck.
“Time, and tide, love — time, and tide. . . .”